Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City
Utah
84108
United States
Tel: 801-584-3600
Fax: 801-584-3640
Website: http://www.myriad.com/
Email: info@myriad.com
About Myriad Genetics, Inc.
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.YEAR FOUNDED:
May 1991
LEADERSHIP:
CEO and Founder: Mark Capone
CMO (Medical): Richard Wenstrup
CFO: Bryan Riggsbee
CSO (Scientific): Jerry Lanchbury
JOBS:
Please click here for Myriad Genetics job opportunities.
CLINICAL TRIAL
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW MYRIAD GENETICS:
Tweets by Myriad Genetics
691 articles about Myriad Genetics, Inc.
-
Legal Fight Over Myriad Genetics, Inc. Breast Cancer Gene Begins
6/9/2010
-
Myriad Genetics, Inc. to Present at the GARP Research and Securities Company Investor Conference
5/27/2010
-
Myriad Genetics, Inc. to Present at the Citi 2010 Global Health Care Conference
5/14/2010
-
Myriad Genetics, Inc. Reports Financial Results for Fiscal 2010 Third Quarter
5/5/2010
-
Myriad Genetics, Inc. Announces Stock Repurchase Program
5/5/2010
-
Myriad Genetics, Inc. to Present at the Ninth Annual JMP Securities Research Conference
4/29/2010
-
Myriad Genetics, Inc. Announces New, Convenient OnDose(TM) Sampling Kit
4/28/2010
-
Myriad Genetics, Inc. Study Shows PTEN Gene is Useful in Predicting Prostate Cancer Recurrence
4/20/2010
-
Myriad Genetics, Inc. to Report Fiscal 2010 Third Quarter Financial Results On May 4
4/14/2010
-
Ruling Rejecting Gene Patents Owned by Myriad Genetics, Inc.
4/5/2010
-
Judge Rejects Myriad Genetics, Inc. Patents on Genes
3/30/2010
-
Myriad Genetics, Inc. Release: Novel Gene Expression Test, PROLARIS(TM), Accurately Predicts Prostate Cancer Recurrence
3/9/2010
-
Myriad Genetics, Inc. Launches PROLARIS(TM): First Diagnostic Test to Predict Prostate Cancer Recurrence
3/3/2010
-
Myriad Genetics, Inc. President and CEO to Ring the NASDAQ Stock Market Opening Bell
3/2/2010
-
Myriad Genetics, Inc. Launches PROLARIS(TM): First Diagnostic Test to Predict Prostate Cancer Recurrence
3/2/2010
-
Myriad Genetics, Inc. Release: New Study Finds 41% of Patients at Community Oncology Practices Were at Risk for Hereditary Breast/Ovarian Cancer
2/25/2010
-
Myriad Genetics, Inc. to Present at the Cowen and Company 30th Annual Health Care Conference
2/24/2010
-
Myriad Genetics, Inc. to Host Investor Day in New York
2/18/2010
-
Myriad Genetics, Inc. to Present at the RBC Capital Markets Healthcare Conference
2/17/2010
-
Myriad Genetics, Inc. Reports Financial Results for Fiscal 2010 Second Quarter
2/3/2010